Difficulty: Medium
Average Score: 68%
Practice
Which of the following statements about pramipexole is accurate?
Correct answer
D
Rationale
In this CNS Stimulants Drugs Pharmacology Quiz question, the correct answer is D) All of the above. Pramipexole is a dopamine agonist that primarily acts on dopamine D2 receptors, hence option A is accurate. It is indeed commonly used as a first-line therapy for Parkinson's disease due to its effectiveness in managing motor symptoms. Additionally, pramipexole can cause postural hypotension as a side effect, making option C also correct.
Option B, stating that pramipexole is commonly a first-line therapy for Parkinson's disease, is incorrect in the context of the question as it is actually true. It is important for learners to understand that pramipexole, along with other dopamine agonists, is often considered before levodopa in the initial management of Parkinson's disease to delay the onset of levodopa-related motor complications.
Educationally, this question is essential for pharmacology students and healthcare professionals as it tests their understanding of pramipexole's pharmacological actions and clinical uses. By knowing that pramipexole activates dopamine D2 receptors, is a first-line therapy for Parkinson's disease, and may cause postural hypotension, learners can make informed decisions in clinical practice when managing patients with Parkinson's disease or other conditions where pramipexole is indicated.
Option B, stating that pramipexole is commonly a first-line therapy for Parkinson's disease, is incorrect in the context of the question as it is actually true. It is important for learners to understand that pramipexole, along with other dopamine agonists, is often considered before levodopa in the initial management of Parkinson's disease to delay the onset of levodopa-related motor complications.
Educationally, this question is essential for pharmacology students and healthcare professionals as it tests their understanding of pramipexole's pharmacological actions and clinical uses. By knowing that pramipexole activates dopamine D2 receptors, is a first-line therapy for Parkinson's disease, and may cause postural hypotension, learners can make informed decisions in clinical practice when managing patients with Parkinson's disease or other conditions where pramipexole is indicated.